MARKET

GOSS

GOSS

Gossamer Bio
NASDAQ
1.125
+0.015
+1.35%
Opening 13:02 05/12 EDT
OPEN
1.140
PREV CLOSE
1.110
HIGH
1.140
LOW
1.070
VOLUME
638.72K
TURNOVER
--
52 WEEK HIGH
1.550
52 WEEK LOW
0.4993
MARKET CAP
255.62M
P/E (TTM)
-4.5018
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GOSS last week (0505-0509)?
Weekly Report · 7h ago
GOSSAMER BIO ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 4d ago
Gossamer Bio To Present Preclinical Data At American Thoracic Society 2025 International Conference
Benzinga · 4d ago
Weekly Report: what happened at GOSS last week (0428-0502)?
Weekly Report · 05/05 09:23
Gossamer Bio: Initiating Hold As Late‐Stage Data Nears Inflection
Seeking Alpha · 05/02 17:21
Weekly Report: what happened at GOSS last week (0421-0425)?
Weekly Report · 04/28 09:25
Gossamer Bio Insider Confidence Rewarded, Stock Hits US$203m Market Cap
Simply Wall St · 04/25 10:00
Weekly Report: what happened at GOSS last week (0414-0418)?
Weekly Report · 04/21 09:25
More
About GOSS
More
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
Recently
Symbol
Price
%Change

Webull offers Gossamer Bio Inc stock information, including NASDAQ: GOSS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOSS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GOSS stock methods without spending real money on the virtual paper trading platform.